Expertise in
21
conditions

Dr. Paul R. Sieber

Urology
Keystone Urology Specialists - Ephrata
175 Martin Avenue, 
Ephrata, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Referral may be required
Before you request
Expertise in
21
conditions
Keystone Urology Specialists - Ephrata
175 Martin Avenue, 
Ephrata, PA 

Overview

Paul Sieber is a Urologist practicing medicine in Ephrata, Pennsylvania.

Dr. Sieber is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Non-Muscle Invasive Bladder Cancer, Orchiectomy, and Ureteroscopy.

Dr. Sieber is board certified in Urology, 1990. He is actively involved in clinical research, co-authoring 33 peer reviewed articles and participating in 9 clinical trials. Dr. Sieber is currently accepting new patients.

Specialties

Urology

Licenses

Urology in PA

Board Certifications

Urology, 1990

Fellowships

Pennsylvania State University College of Medicine

Hospital Affiliations

Wellspan Good Samaritan Hospital
Lancaster General Hospital
Milton S Hershey Medical Center
Wellspan Ephrata Community Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Keystone Urology Specialists - Ephrata
175 Martin Avenue, Ephrata, PA 17522
Other Locations
Keystone Urology Specialists - Lancaster - 2106 Building
2106 Harrisburg Pike, Suite 200, Lancaster, PA 17601

Additional Areas of Focus

Dr. Sieber has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Prostate Cancer
Bladder Cancer
Kidney Stones
Testicular Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: July 09, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological
Study Drugs: Aglatimagene besadenovec, Valacyclovir
Study Phase: Phase 3
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological, Drug
Study Drugs: Aglatimagene Besadenovec, Valacyclovir
Study Phase: Phase 2
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Enrollment Status: Completed
Publish Date: September 25, 2024
Intervention Type: Biological, Other
Study Drugs: Engineered Oncolytic Adenovirus, Pembrolizumab, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 2
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Terminated
Publish Date: June 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive Versus Indolent Prostate Cancer
Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive Versus Indolent Prostate Cancer
Enrollment Status: Completed
Publish Date: June 12, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Enrollment Status: Terminated
Publish Date: June 23, 2022
Intervention Type: Diagnostic test
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

33 Total Publications

DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.
Journal: Prostate cancer and prostatic diseases
Published: June 11, 2025
Similar Doctors
Expertise in
34
conditions
Expertise in
34
conditions
Referral may be required

Office

500 University Dr Ste 3100, 
Hershey, PA 
 (24.7 miles away)
717-531-8849
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jay Raman is a Urologist practicing medicine in Hershey, Pennsylvania. Dr. Raman is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Renal Cell Carcinoma (RCC), Nephrectomy, and Ureteroscopy.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Penn Urology Perelman

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (54.9 miles away)
215-662-2891
Languages Spoken:
English
See accepted insurances

Trinity Bivalacqua is a Urologist practicing medicine in Philadelphia, Pennsylvania. Dr. Bivalacqua is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Prostatectomy.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Huntingdon Pike

8 Huntingdon Pike, 
Rockledge, PA 
 (58.4 miles away)
888-369-2427
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Uzzo is a Urologist practicing medicine in Rockledge, Pennsylvania. Dr. Uzzo is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Renal Oncocytoma, Nephrectomy, and Cystectomy. Dr. Uzzo is board certified in American Board Of Urology.

Frequently Asked Questions about Dr. Paul R. Sieber

How do I make an appointment with Dr. Paul R. Sieber?

You can book an appointment with Dr. Paul R. Sieber by calling their office at 717-393-1771. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul R. Sieber a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul R. Sieber is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul R. Sieber specialize in?

While Dr. Paul R. Sieber is a Urology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Non-Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Urology.

Does Dr. Paul R. Sieber participate in research or clinical trials?

Yes. Dr. Paul R. Sieber has published 33 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Paul R. Sieber's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul R. Sieber accept my insurance?

Dr. Paul R. Sieber accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 717-393-1771 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sieber's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile